Daiichi Sankyo announced the company has terminated the development program for their GPR20 directed antibody drug conjugate DS-6157 due to a lack of clinical response. The company…
GlaxoSmithKline and Merck KGaA announced a joint decision to terminate their global collaboration on bintrafusp alfa, effective September 30, 2021. Bintrafusp alfa is an investigational bifunctional fusion protein…
Enanta Pharmaceuticals provided an update on its two clinical stage farnesoid X receptor (FXR) agonists, EDP-305 and EDP-297, both in development for the treatment of non-alcoholic steatohepatitis (NASH). Following…
Theravance announced top-line results from a Phase 3 randomized, double-blind, placebo-controlled multi-center SEQUOIA study assessing the safety and efficacy of ampreloxetine compared to placebo for…
Astellas announced that a patient participating in the phase 1/2 ASPIRO trial has died. The trial is evaluating AT132 in patients with X-linked Myotubular Myopathy…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
